Progeria is exceptionally rare, affecting one in 4 million live births worldwide. It is estimated that about 400 people are living with the condition globally at any one time. The disease affects both sexes and all ethnic groups.

Progeria is caused by a sporadic, spontaneous mutation in the LMNA (lamin-A) gene, which encodes for a protein that is part of the structural scaffolding for the cell nucleus. The mutation produces a truncated version of this protein, called progerin, which destabilizes the nucleus, leading to progressive cellular damage, premature cell death, and the rapid aging phenotype. The mutation is autosomal dominant (see RareShare guide on genetic inheritance), meaning only one copy of the mutated gene is necessary to cause the disease. However, most cases result from a de novo (new) mutation and are not inherited from either parent.

The LMNA gene makes a protein called Lamin A, which is an important protein found in the cell nucleus (the part of each cell that contains the DNA), and helps maintain the shape and function of the cell. The mutation compromises that cell integrity, causing progeria. With the genetic alteration, the LMNA gene produces an abnormal lamin A protein called progerin. In children with progeria, progerin is produced by many cells in the body, and therefore affects many of the body’s systems such as the blood vessels, skin and bones. As the children age, progerin builds up in the cells and causes progressive disease. Studies of this pathway may help investigators better understand the normal aging process.

Progeria symptoms typically manifest between 9 and 24 months of age. Importantly, intellectual and motor development remain completely normal. Clinical signs include:

• Growth & Development: Severe failure to thrive, below-average height and weight, and a profound loss of body fat and muscle mass.

• Physical Appearance: A disproportionately large head compared to the face, prominent eyes that may not close fully, a small lower jaw, a thin nose with a "beaked" tip, prominent scalp veins, and a high-pitched voice.

• Dermatological: Generalized hair loss (alopecia) including eyelashes and eyebrows, alongside thin, wrinkled, and spotted skin.

• Musculoskeletal: Stiff joints, delayed and abnormal tooth eruption, skeletal abnormalities (fragile bones, thin ribs), and hip dislocations.

• Cardiovascular: Progressive, severe atherosclerosis (hardening and narrowing of the arteries), which restricts blood flow to the heart and brain.

• Other features:  Hearing loss, insulin resistance, delayed or absent puberty.

Although most are born looking healthy, children with progeria begin to display many characteristics of accelerated aging at around 9-24 months of age. Progeria signs include growth failure, loss of body fat and hair, skin changes, stiffness of joints, hip dislocation, generalized atherosclerosis, cardiovascular (heart) disease and stroke. Remarkably, the intellect of children with progeria is unaffected, and despite the unusual physical changes in their young bodies, these extraordinary children are intelligent, courageous, and full of life. The children have a remarkably similar appearance, despite differing ethnic backgrounds.

Due to its distinct physical traits, progeria is often initially suspected based on clinical evaluation and the child's physical appearance, including growth failure, premature aging appearance, alopecia and characteristic facial features. Confirmation is achieved by identifying a pathogenic mutation in the LMNA gene through genetic sequencing. Once diagnosed, additional assessments of cardiovascular function (echocardiograms, EKGs), vascular imaging, bone density and growth are typically done to determine disease severity and to monitor complications.

The Progeria Research Foundation (PRF) provides a genetic test for Progeria through The PRF Diagnostic Testing Program. 

While there is currently no cure for progeria, the treatment landscape has shifted significantly from purely symptomatic management to disease-modifying therapies.

• Targeted Therapy: In 2020, the FDA approved Lonafarnib (Zokinvy), a farnesyltransferase inhibitor (FTI). It is currently the only approved drug that targets the disease's root cause by blocking the enzyme that helps anchor the toxic progerin to the cell nucleus, thereby reducing its accumulation. It has been shown to improve survival and cardiovascular outcomes.

• Symptomatic Management:

  • Low-dose daily aspirin to prevent blood clots, heart attacks, and strokes.

  • Statins and anticoagulants to manage cardiovascular health.

  • Physical and occupational therapy to maintain joint mobility.

  • Routine cardiovascular monitoring and high-calorie dietary supplements to support growth.

  • Dental care and hearing assessments.

• Research and Trials: Ongoing clinical trials are exploring newer therapies, including drugs that promote progerin degradation (like Progerinin) and highly promising gene-editing techniques (such as base editing) aimed at permanently correcting the LMNA mutation at the DNA level.

Without targeted medical treatment, the average life expectancy for a child with progeria is roughly 14.5 years. The primary cause of mortality is almost exclusively complications from severe atherosclerosis, resulting in heart failure or strokes.

With the introduction of Lonafarnib and comprehensive cardiac care, life expectancy has increased. Treated patients now live to an average of almost 20 years, with a few individuals living into their early-to-mid 20s. With children living longer due to lonafarnib therapy, physicians are now seeing aortic stenosis (narrowing of a critical heart valve) as a new problem in older children and young adults with progeria, which may be amenable to lifesaving surgery.

1. Arun A, Nath AR, Thankachan B, Unnikrishnan MK. 2024. “Hutchinson-Gilford progeria syndrome: unraveling the genetic basis, symptoms, and advancements in therapeutic approaches.” Ther Adv Rare Dis. 5:26330040241305144. doi: 10.1177/26330040241305144. PMID: 39691184; PMCID: PMC11650505.

2. Cisneros B, García-Aguirre I, De Ita M, Arrieta-Cruz I, Rosas-Vargas H. 2023. “Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives.” Arch Med Res. 54(5):102837. doi: 10.1016/j.arcmed.2023.06.002. Epub 2023 Jun 28. PMID: 37390702.

3. Gordon LB, Brown WT, Collins FS. 2025. “Hutchinson-Gilford Progeria Syndrome.” In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1121/.

4. The Progeria Research Foundation. Progeria 101 FAQ. progeriaresearch.org.

5. National Organization for Rare Disorders (NORD):  Hutchinson-Gilford progeria syndrome.